Alnylam Pharmace. buy Subdi
Summary
This prediction ended on 06.09.18 with a price of €105.44. With a performance of -4.71%, the BUY prediction for Alnylam Pharmace. by Subdi closed slightly in the red. Subdi has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | 4.797% | 4.797% | -3.119% | 45.158% |
| iShares Core DAX® | -2.486% | 0.323% | 0.748% | 51.017% |
| iShares Nasdaq 100 | -4.401% | 1.587% | 32.085% | 87.968% |
| iShares Nikkei 225® | -4.295% | 0.970% | 50.000% | 61.272% |
| iShares S&P 500 | -2.199% | 2.005% | 22.599% | 65.117% |
Comments by Subdi for this prediction
In the thread Alnylam Pharmace. diskutieren
Subdi stimmt der Buy-Einschätzung von stratec zu
Subdi stimmt am 31.08.2018 der Buy-Einschätzung von stratec mit dem Kursziel 146,78$ zu.
Überschrift: Alnylam with its first new drug application and multiple clinical read-outs in 2018
Stopped prediction by Subdi for Alnylam Pharmace.
Alnylam Pharmace.
27.10.18
08.11.18
08.11.18
Alnylam Pharmace.
10.09.18
12.09.18
12.09.18